The company is trading at a high EV/EBITDA of 67.13. Company has contingent liabilities of 4,875.59 Cr. Lupin is recently going through a rough patch, especially on the US generics front due to plant compliance issues besides margins pressure Q3FY22 Results: Lupin’s revenues were inline driven by India and US while margins were impacted due to one-off expenses and continued price erosion in US. Company has a poor ROE of 6.93 over the past 3 years. The company has shown a poor revenue growth of 3.10 for the Past 3 years. If a stock trades below 50-DMA and 200-DMA, it usually means the immediate trend is upward. The company has shown a poor profit growth of -2.18 for the Past 3 years. This week, the focus will be on the upcoming RBI policy, wherein economists are expecting the Central. The key benchmark indices are likely to start the action-packed week on a quiet note taking cues from the global peers.
The 200-DMA of the stock stood at 839.51 on June 13, while the 50-DMA was at 697.74. Motilal Oswal recommended Neutral rating on Lupin with a target price of Rs 590 in its research report dated May 19, 2022. Stocks to watch today: Shares of firms like Wipro, HDFC Bank, Lupin, DMart, and others will be in focus in Mondays trade. as of 3 while foreign and domestic institutional investors owned 14.65 per cent and 15.72 per cent, respectively. Promoters held 46.5 per cent in Lupin Ltd. The stock's beta value, which measures volatility in relation to the broader market, stood at 0.75. In the BSE500 pack, 28 stocks traded in the green, while 473 stocks were in the red. Return on equity (ROE) was at -12.57 per cent, according to exchange data. The stock traded at a price-to-earning (P/E) multiple of -18.4, while the price-to-book value ratio stood at 2.79. commanded a market value of Rs 28114.08 crore, according to BSE. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.īy using this site, you agree to the Terms of Service and Privacy Policy.The stock of Lupin Ltd. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. All timestamps are reflected in IST (Indian Standard Time).ĭISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. (for corporate data, historical price & volume, F&O data). As on 31-03-2022, the company has a total of 45.45 Crore shares outstanding.ĭATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd.
The company’s top management includes Mrs.Manju D Gupta, Dr.Punita Kumar-Sinha, Mr.K B S Anand, Ms.Christine Mundkur, Mr.Jean-Luc Belingard, Mr.Ramesh Swaminathan, Ms.Vinita Gupta, Mr.Nilesh D Gupta, Dr.Kamal K Sharma, Mr.Mark D McDade. Company has reported net profit after tax of Rs -511.89 Crore in latest quarter. For the quarter ended 31-03-2022, the company has reported a Consolidated Total Income of Rs 3,898.71 Crore, down 7.06 % from last quarter Total Income of Rs 4,194.99 Crore and up 1.49 % from last year same quarter Total Income of Rs 3,841.32 Crore. key Products/Revenue Segments include Pharmaceuticals, Export Incentives, Other Operating Revenue and Other Services for the year ending 3. Lupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 28,800.08 Crore) operating in Pharmaceuticals sector.